|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.8589 - 0.8589|
|52 Week Range||0.8000 - 1.7400|
|Beta (5Y Monthly)||2.23|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The big shareholder groups in Mesoblast Limited ( ASX:MSB ) have power over the company. Institutions will often hold...
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with US$25.8 million in the comparativ
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.